4//SEC Filing
Salkind Gene 4
Accession 0001683168-25-001392
CIK 0001759186other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 5:28 PM ET
Size
6.0 KB
Accession
0001683168-25-001392
Insider Transaction Report
Form 4
Salkind Gene
Director
Transactions
- Award
Non-qualified Stock Options (right to buy)
2025-03-04+5,700→ 8,950 totalExercise: $10.56→ Common Stock (5,700 underlying)
Footnotes (4)
- [F1]On March 4, 2025, the reporting person received a grant of 5,700 stock options, as non-qualified options, under the 2022 equity incentive plan.
- [F2]The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Capital Market on the day of grant.
- [F3]Non-qualified options will vest over 1 year, in four equal installments, with the first 25% vesting on 3/31/2025, the next 25% vesting on 6/30/2025, the next 25% vesting on 9/30/25, and the final 25% vesting on 12/31/25.
- [F4]Expiration date is ten years from the day of grant.
Documents
Issuer
Coeptis Therapeutics Holdings, Inc.
CIK 0001759186
Entity typeother
Related Parties
1- filerCIK 0001592481
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 5:28 PM ET
- Size
- 6.0 KB